Decibel Therapeutics, Inc.

NasdaqGS:DBTX Stock Report

Market Cap: US$124.3m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Decibel Therapeutics Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Laurence Reid

Chief executive officer

US$1.2m

Total compensation

CEO salary percentage44.47%
CEO tenure3.8yrs
CEO ownershipn/a
Management average tenure2.1yrs
Board average tenure2.4yrs

Recent management updates

Recent updates

Analysis Article • Aug 10

Here's Why We're Watching Decibel Therapeutics' (NASDAQ:DBTX) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Feb 07

Is Decibel Therapeutics (NASDAQ:DBTX) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Oct 17

Decibel stock surges 18% as FDA clears hearing loss gene therapy to enter trial

The U.S. Food and Drug Administration (FDA) granted clearance to Decibel Therapeutics' (NASDAQ:DBTX) investigational new drug (IND) application for starting a phase 1/2 trial of gene therapy DB-OTO to treat hearing loss in pediatric patients. DB-OTO is aimed to provide durable hearing in individuals born with profound congenital hearing loss due to deficiency of a protein called otoferlin, according to the company. Decibel said DB-OTO is being developed in collaboration with Regeneron Pharmaceuticals (NASDAQ:REGN) and is an adeno-associated virus (AAV)-based gene therapy product candidate. The company added that a one-time administration of DB-OTO had shown a production of otoferlin protein and durable auditory brainstem responses to sound in a congenitally deaf rodent disease model. Decibel expects the first two participants in the U.S. portion of the phase 1/2 trial will be as young as seven years of age and afterwards will include children as young as two years of age, and infants below two years of age. The company noted that DB-OTO is the second product candidate after DB-020 in its pipeline to advance into clinical testing. DBTX +18.24% to $3.50 premarket Oct. 17
Analysis Article • Sep 01

We Think Decibel Therapeutics (NASDAQ:DBTX) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jul 06

Decibel Therapeutics: Gene Therapies For Hearing Loss

Decibel is a category leader in developing new medicines for hearing and balance disorders. The company's lead asset, DB-OTO, has several upcoming catalysts over the next 18 months that can validate Decibel's platform. With a unique business model, Decibel is a compelling investment positioned to rapidly expand their pipeline and partnerships pending DB-OTO.

CEO Compensation Analysis

How has Laurence Reid's remuneration changed compared to Decibel Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-US$63m

Mar 31 2023n/an/a

-US$62m

Dec 31 2022US$1mUS$548k

-US$63m

Sep 30 2022n/an/a

-US$60m

Jun 30 2022n/an/a

-US$60m

Mar 31 2022n/an/a

-US$55m

Dec 31 2021US$801kUS$522k

-US$54m

Sep 30 2021n/an/a

US$576k

Jun 30 2021n/an/a

US$7m

Mar 31 2021n/an/a

US$8m

Dec 31 2020US$4mUS$574k

US$7m

Compensation vs Market: Laurence's total compensation ($USD1.23M) is above average for companies of similar size in the US market ($USD738.70K).

Compensation vs Earnings: Laurence's compensation has increased whilst the company is unprofitable.

CEO

Laurence Reid (59 yo)

3.8yrs
Tenure
US$1,232,276
Compensation

Dr. Laurence E. Reid, Ph D., serves as President, Chief Executive Officer and until September 25, 2023 served as Director at Decibel Therapeutics, Inc. since January 2020 and served as its consultant since...

Leadership Team

NamePositionTenureCompensationOwnership
Laurence Reid
President & CEO3.8yrsUS$1.23mno data
Anna Trask
Executive VP & Chief People Officer5.8yrsUS$618.23k0%
$ 0
John Lee
Executive VP & Chief Development Officer7.1yrsUS$733.16k0%
$ 0
M. Liberman
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Gabriel Corfas
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Ulrich Müller
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Albert S. Edge
Co-Founder & Member of Scientific Advisory Boardno datano datano data
James Murphy
Interim CFO1yrno datano data
Elaine Cope
Vice President of Operations2.1yrsno datano data
Geoff Horwitz
VP of Corporate Development & Head of Business Developmentless than a yearno datano data
Vassili Valayannopoulos
VP and Head of Clinical Research & Developmentless than a yearno datano data
2.1yrs
Average Tenure
65yo
Average Age

Experienced Management: DBTX's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
M. Liberman
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Gabriel Corfas
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Ulrich Müller
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Albert S. Edge
Co-Founder & Member of Scientific Advisory Boardno datano datano data
Glenn Pierce
Member of Scientific Advisory Board2.4yrsno datano data
Constance Cepko
Member of Scientific Advisory Board2.4yrsno datano data
Guangping Gao
Member of Scientific Advisory Board2.4yrsno datano data
Alan Cheng
Member of Scientific Advisory Boardno datano datano data
David Ginty
Member of Scientific Advisory Boardno datano datano data
Michael Greenberg
Member of Scientific Advisory Boardno datano datano data
Dwight Bergles
Member of Scientific Advisory Boardno datano datano data
Matthew Kelley
Member of Scientific Advisory Board2.4yrsno datano data
2.4yrs
Average Tenure
68yo
Average Age

Experienced Board: DBTX's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/10/06 14:21
End of Day Share Price 2023/09/22 00:00
Earnings2023/06/30
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Decibel Therapeutics, Inc. is covered by 8 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Huidong WangBarclays
Matthew LuchiniBMO Capital Markets Equity Research